General Information
Version
3
Revision date
2024-09-30
Product name
CHEMKLEEN 314RA-GM
1.2.1 Relevant identified uses
Industrial applications
1.2.2. Uses advised against
Coating. Paints. Painting-related materials
Manufacturer Name
Pretreatment and Specialty Products
Emergency telephone
1-888-774-2001
Icons in SDS
Company Information
company name
Pretreatment and Specialty Products
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H227, H316, H319
Hazard statements
Code
Statements
H227
Combustible liquid
Section 2
SECTION 2: Hazards identification
Classification of the substance or mixture FLAMMABLE LIQUIDS - Category 4 SKIN IRRITATION - Category 3 EYE IRRITATION - Category 2A Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 2.2% (oral), 2.2% (dermal), 3.5% (inhalation)
Signal word
Warning
Hazard statements
H227 - Combustible liquid. H316 - Causes mild skin irritation. H319 - Causes serious eye irritation.
Prevention
P280 - Wear protective gloves, protective clothing and eye or face protection. P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P264 - Wash thoroughly after handling.
Response
P332 + P313 - If skin irritation occurs: Get medical advice or attention. P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 - If eye irritation persists: Get medical advice or attention.
Storage
Not applicable.
Disposal
P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Other hazards which do not result in classification
Emits toxic fumes when heated. See toxicological information (Section 11)
2.1 Classification of the substance or mixture
FLAMMABLE LIQUIDS - Category 4 substance or mixture SKIN IRRITATION - Category 3 EYE IRRITATION - Category 2A Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 2.2% (oral), 2.2% (dermal), 3.5% (inhalation)